- Home
- HBB vs SCLXW Comparison
HBB vs SCLXW Comparison
Compare HBB & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- SCLXW
- Stock Information
- Founded
- HBB 1904
- SCLXW N/A
- Country
- HBB United States
- SCLXW United States
- Employees
- HBB N/A
- SCLXW 113
- Industry
- HBB Home Furnishings
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- SCLXW Health Care
- Exchange
- HBB Nasdaq
- SCLXW Nasdaq
- Market Cap
- HBB 292.6M
- SCLXW N/A
- IPO Year
- HBB 2017
- SCLXW 2021
- Fundamental
- Price
- HBB $16.48
- SCLXW $0.22
- Analyst Decision
- HBB
- SCLXW
- Analyst Count
- HBB 0
- SCLXW 0
- Target Price
- HBB N/A
- SCLXW N/A
- AVG Volume (30 Days)
- HBB 54.1K
- SCLXW N/A
- Earning Date
- HBB 10-30-2024
- SCLXW N/A
- Dividend Yield
- HBB 2.75%
- SCLXW N/A
- EPS Growth
- HBB 107.04
- SCLXW N/A
- EPS
- HBB 1.88
- SCLXW N/A
- Revenue
- HBB $647,834,000.00
- SCLXW N/A
- Revenue This Year
- HBB $4.60
- SCLXW N/A
- Revenue Next Year
- HBB N/A
- SCLXW N/A
- P/E Ratio
- HBB $8.82
- SCLXW N/A
- Revenue Growth
- HBB 5.30
- SCLXW N/A
- 52 Week Low
- HBB $14.34
- SCLXW N/A
- 52 Week High
- HBB $31.78
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- HBB 22.07
- SCLXW N/A
- Support Level
- HBB $16.12
- SCLXW N/A
- Resistance Level
- HBB $18.39
- SCLXW N/A
- Average True Range (ATR)
- HBB 0.89
- SCLXW 0.00
- MACD
- HBB 0.01
- SCLXW 0.00
- Stochastic Oscillator
- HBB 0.02
- SCLXW 0.00
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.